Mon, May 18, 2026
[Archive]
Articles In Press
Back to the articles list |
Back to browse issues page
1- Department of Medical Laboratory Sciences, School of Paramedical, Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences
4- Department of Molecular Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran ,maleki.hem@gmail.com
2- Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences
4- Department of Molecular Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran ,
Abstract: (11 Views)
Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia characterized by the t(15;17) translocation, generating the PML-RARA fusion gene. This fusion occurs in three primary variants: bcr1, bcr2, and bcr3. In Iran, bcr1 is the most prevalent (~73%), bcr3 accounts for ~27%, and bcr2 is virtually undetected. Given this distribution, developing a locally optimized method for detecting bcr1 is essential for accurate and rapid identification of this fusion and crucial for monitoring patient response.
Methods: A synthetic 130-bp PML-RARA bcr1 fragment was cloned into pUC57, and insertion was analyzed by digestion with XbaI and HindIII and agarose gel electrophoresis. RNA from APL patient samples was reverse-transcribed into cDNA, serving as a template for reverse-transcription quantitative polymerase chain reaction (RT-qPCR) with PML-RARA-specific primers and β-actin as the reference. Each run included APL samples, plasmid-based positive controls, healthy negative controls, and no-template controls. Amplification and melt-curve analysis confirmed assay specificity and reproducibility.
Results: The recombinant pUC57-PML-RARA plasmid was verified by XbaI/HindIII digestion. RT-qPCR showed specific amplification of PML-RARA in plasmid controls (Ct 15-20) and APL patient samples (Ct 22-26), with no amplification in negative controls. Melt curve analysis showed single, sharp peaks, confirming specificity, and agarose gel electrophoresis verified the expected product sizes. Relative quantification indicated approximately 26-fold higher expression in plasmid controls compared to patient samples, with high reproducibility at a 1:20 dilution.
Conclusion: This preliminary assessment shows sufficient specificity and reliability for detecting the PML-RARA bcr1 variant, providing a foundation for further validation in the future.
Methods: A synthetic 130-bp PML-RARA bcr1 fragment was cloned into pUC57, and insertion was analyzed by digestion with XbaI and HindIII and agarose gel electrophoresis. RNA from APL patient samples was reverse-transcribed into cDNA, serving as a template for reverse-transcription quantitative polymerase chain reaction (RT-qPCR) with PML-RARA-specific primers and β-actin as the reference. Each run included APL samples, plasmid-based positive controls, healthy negative controls, and no-template controls. Amplification and melt-curve analysis confirmed assay specificity and reproducibility.
Results: The recombinant pUC57-PML-RARA plasmid was verified by XbaI/HindIII digestion. RT-qPCR showed specific amplification of PML-RARA in plasmid controls (Ct 15-20) and APL patient samples (Ct 22-26), with no amplification in negative controls. Melt curve analysis showed single, sharp peaks, confirming specificity, and agarose gel electrophoresis verified the expected product sizes. Relative quantification indicated approximately 26-fold higher expression in plasmid controls compared to patient samples, with high reproducibility at a 1:20 dilution.
Conclusion: This preliminary assessment shows sufficient specificity and reliability for detecting the PML-RARA bcr1 variant, providing a foundation for further validation in the future.
Keywords: Key words: Acute Promyelocytic Leukemia (APL), PML-RARA fusion, bcr1 variant, Translocation t (15, 17)
Type of Study: Original Research Article |
Subject:
Medical Biology
Received: 2025/11/13 | Accepted: 2025/12/6
Received: 2025/11/13 | Accepted: 2025/12/6
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Journal of Advances in Medical and Biomedical Research by Farname Inc. is licensed under CC BY-NC 4.0
